How a Pharmaceutical Company Streamlined Clinical Trial Management With Low-Code Workflows

Clinical trials are the backbone of pharmaceutical innovation, yet the processes that underpin them have remained stubbornly analog and inefficient for decades. When a mid-sized pharmaceutical company specializing in oncology therapeutics set out to accelerate its drug development pipeline, it discovered that its clinical trial management systems were contributing to delays that cost millions in potential revenue and, more importantly, delayed treatments for patients awaiting new therapies. This case study examines how the company deployed a low-code platform to digitize and automate clinical trial management workflows, reducing trial setup time by 60 percent, cutting data collection errors by 85 percent, and accelerating regulatory submissions by an average of 4.5 months per study.

The Critical Role of Clinical Trial Management in Drug Development

Bringing a new drug to market is among the most complex and expensive endeavors in the business world. According to the Tufts Center for the Study of Drug Development, the average cost of developing a new prescription drug that gains market approval is estimated at $2.6 billion, with clinical trials accounting for a substantial portion of that expenditure. The same research indicates that the average clinical trial takes 7 to 10 years from first-in-human studies to regulatory approval, and that timeline has been extending rather than contracting over recent decades.

The pharmaceutical company in this case study, which we will refer to as OncoCure Therapeutics, faced specific challenges in its clinical trial operations. The company had a promising pipeline of oncology treatments targeting lung cancer, breast cancer, and rare pediatric cancers, but its ability to move compounds through clinical development was constrained by outdated, paper-intensive trial management processes. Clinical research associates spent approximately 30 percent of their time on administrative data entry and verification tasks rather than on higher-value activities like site monitoring and patient safety oversight.

The Complexity of Modern Clinical Trials

Modern clinical trials involve a staggering array of interconnected activities and stakeholders. A single Phase III trial might involve 200 or more clinical sites across 20 countries, thousands of patients, dozens of data collection points per patient visit, multiple regulatory authorities with different reporting requirements, and stringent data integrity standards. The FDA's clinical research guidelines emphasize the critical importance of data quality, patient safety monitoring, and regulatory compliance throughout the trial lifecycle.

OncoCure Therapeutics was managing 14 active clinical trials simultaneously, each with its own protocol, data management plan, and regulatory requirements. The company's clinical operations team relied on a patchwork of systems — a commercial clinical trial management system (CTMS) that was difficult to customize, spreadsheets for tracking patient enrollment and data collection, email for communication with clinical sites, and paper documents for many critical workflow steps including case report form reviews and query resolution.

The Challenge: System Limitations and Process Inefficiencies

OncoCure's clinical operations leadership identified several systemic problems that were impeding trial execution:

Rigid Commercial Systems

The company's commercial CTMS was implemented five years earlier at a cost of $3 million, but it had proven inflexible and difficult to adapt to the company's specific workflows. Any change to the system required vendor involvement, a formal change request, and typically three to six months for implementation. This rigidity meant that when the company launched a new trial with a unique protocol design, the CTMS often could not support the required data collection or workflow without expensive customizations. Clinical teams frequently bypassed the system entirely, maintaining shadow spreadsheets and manual tracking processes to manage their trials effectively.

Data Fragmentation and Manual Processes

Critical trial data was scattered across multiple systems and formats. Patient enrollment data lived in the CTMS, but site monitoring reports were in email attachments, adverse event logs were in spreadsheets, and regulatory submission documents were in shared folders with inconsistent naming conventions. Clinical research associates spent an average of 15 hours per week manually reconciling data between systems, entering the same information multiple times, and tracking down missing or inconsistent data points.

The manual data entry processes were not just inefficient — they were error-prone. OncoCure's internal quality audits revealed that data entry errors affected 3.2 percent of all case report form fields, requiring extensive query resolution efforts that delayed data lock and analysis. In a regulated environment where data integrity is paramount, these error rates were deemed unacceptable by the company's quality assurance leadership.

Regulatory Submission Delays

The cumulative effect of system rigidity, data fragmentation, and manual processes was most visible in regulatory submissions. OncoCure's average timeline from last patient visit to regulatory submission was 8.3 months, compared to the industry benchmark of 5 to 6 months for well-managed trials. Each month of delay in regulatory submission represented approximately $1.2 million in lost potential revenue for the company's lead asset, creating enormous pressure to improve trial closeout efficiency.

The Solution: A Low-Code Clinical Trial Management Platform

Rather than replacing its existing CTMS with another commercial system that might have similar limitations, OncoCure's clinical operations and IT teams jointly pursued a strategy of building a complementary platform on a low-code application platform. The low-code platform would serve as an orchestration layer, connecting to the existing CTMS where appropriate and adding new capabilities where the commercial system fell short.

Developing the Clinical Trial Workflow Automation Suite

The low-code development effort was organized into several application modules, each addressing a specific pain point in the clinical trial lifecycle:

• Study startup automation — digitized and automated the process of setting up new clinical trials, including site selection workflows, investigator contract management, regulatory document collection, and ethics committee submission tracking
• Patient enrollment tracking — real-time dashboards showing enrollment progress against targets across all active trials, with automated alerts when enrollment lagged behind projections
• Site monitoring and management — integrated workflows for scheduling and tracking site monitoring visits, capturing findings, managing corrective actions, and reporting to study teams
• Data query management — automated data query generation, routing, resolution tracking, and escalation for case report form discrepancies
• Adverse event reporting — structured workflows for adverse event capture, severity assessment, causality evaluation, and regulatory reporting per FDA and EMA requirements
• Regulatory submission preparation — document management, version control, review workflows, and submission package assembly for regulatory filings

Each module was developed iteratively, with the low-code platform's visual development tools enabling rapid prototyping and user feedback cycles. OncoCure's clinical operations team members — who were domain experts but not software developers — actively participated in configuring workflows and business rules within the platform. This collaborative development approach ensured that the applications closely matched actual clinical trial workflows rather than idealized versions that might not reflect operational reality.

Integration Architecture

The low-code platform was integrated with OncoCure's existing CTMS, electronic data capture system, document management platform, and human resources system. The integration strategy was designed to leverage existing investments while extending capabilities where needed. Patient data, visit schedules, and case report form data remained in the EDC system, but the low-code platform provided the workflow layer that orchestrated how this data was reviewed, queried, and processed.

The platform's pre-built integration connectors for healthcare and life sciences systems significantly reduced the integration effort. Where custom integrations were needed, the platform's API management capabilities allowed OncoCure's small integration team to build and test new connectors in days rather than weeks. Deloitte's life sciences research emphasizes the importance of interoperability in modern clinical trial technology stacks, noting that the ability to connect systems and data sources is a critical success factor for trial digitization initiatives.

Implementation Journey and Timeline

The low-code clinical trial management platform was implemented over a 12-month period, with each module deployed as it was completed rather than waiting for the full suite to be ready.

Months 1-3: Study Startup Automation Pilot

The first module addressed study startup, which was the most time-consuming and paper-intensive phase of clinical trial management. The process of setting up a new trial involved over 200 individual tasks, 40-plus document types, and interactions with multiple external stakeholders including clinical sites, ethics committees, regulatory authorities, and contract research organizations. OncoCure's target was to reduce study startup time from an average of 6.5 months to 3 months.

The low-code application digitized the entire study startup process, providing automated task assignment, document collection workflows, status tracking dashboards, and stakeholder communication templates. The pilot was run on three new trials and demonstrated a reduction in study startup time to 3.2 months, nearly achieving the target on the first attempt. The pilot also revealed several areas for improvement in the next iteration, including better integration with ethics committee submission systems and more automated document validation checks.

Months 4-7: Patient Enrollment and Site Monitoring

The second phase addressed patient enrollment tracking and site monitoring management. These were areas where the existing CTMS offered some functionality, but the capabilities were limited and difficult to customize. OncoCure's approach was to use the low-code platform to build a more user-friendly and comprehensive interface on top of the CTMS data.

The patient enrollment dashboard provided real-time visualization of enrollment trends across all trials, with the ability to drill down by country, site, investigator, and patient demographics. Automated enrollment alerts notified study teams when sites fell behind their enrollment targets, enabling early intervention. The site monitoring module digitized the entire monitoring visit lifecycle, from visit scheduling and preparation through findings documentation, issue tracking, and follow-up verification.

The impact was immediate. Clinical research associates reported a 40 percent reduction in time spent on enrollment tracking and monitoring documentation. Site monitors could complete their visit reports in the field using a mobile app, eliminating the backlog of report writing that had previously consumed their office days.

Months 8-12: Data Management and Regulatory Submission

The final phase addressed data query management, adverse event reporting, and regulatory submission preparation. These were the most technically complex modules, requiring careful integration with the electronic data capture system and compliance with regulatory requirements.

The data query management module automated the process of identifying, generating, and tracking data queries. When data discrepancies were identified in case report forms, the system automatically generated queries, routed them to the appropriate clinical site, tracked response times, and escalated unresolved queries according to configurable business rules. The module also provided study teams with dashboards showing query status and trends, helping them identify systemic data quality issues early.

The adverse event reporting workflow ensured that all adverse events were captured, assessed, and reported within regulatory timelines. The system integrated with the company's safety database and provided configurable workflows for different types of events and reporting requirements across jurisdictions.

Measurable Results and Business Impact

The clinical trial management transformation produced significant improvements across multiple dimensions. OncoCure's internal metrics, measured 18 months after the initial pilot deployment, showed:

Metric	Before	After	Improvement
Study startup time	6.5 months	2.8 months	57 percent reduction
Data entry error rate	3.2 percent	0.5 percent	84 percent reduction
Query resolution time	18 days	4 days	78 percent reduction
Last patient to submission time	8.3 months	3.8 months	54 percent reduction
CRA administrative time	30 percent	8 percent	73 percent reduction
Patient enrollment rate (vs target)	72 percent	94 percent	+22 percentage points
Regulatory submission cycle time	4.2 months	1.8 months	57 percent reduction
Site satisfaction score	6.8/10	8.9/10	+31 percent

Financial Impact

The accelerated clinical timelines produced substantial financial benefits. OncoCure estimated that reducing study startup time by 3.7 months per trial saved approximately $1.5 million per trial in direct costs, including reduced site activation fees, lower internal resource requirements, and shorter patient recruitment periods. With 14 active trials, the cumulative direct cost savings were estimated at $21 million annually.

The reduction in last-patient-to-submission time from 8.3 months to 3.8 months had an even more significant financial impact. For OncoCure's lead oncology asset, which had projected peak annual sales of $800 million, each month of earlier submission translated to earlier potential market launch and additional revenue. The 4.5-month reduction in submission timeline meant the company could potentially bring its drug to market nearly half a year earlier, representing hundreds of millions in potential incremental revenue over the product lifecycle.

Quality and Compliance Improvements

The reduction in data entry errors from 3.2 percent to 0.5 percent was particularly significant for regulatory compliance. Industry guidelines from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) emphasize data integrity as a cornerstone of clinical trial quality. The automated data query management system reduced query resolution time by 78 percent and virtually eliminated the backlog of unresolved queries that had previously accumulated at the end of each trial.

The improved data quality also had downstream benefits for statistical analysis and regulatory review. The company's biostatistics team reported that data cleaning and validation cycles were completed in half the time, allowing more time for the statistical analysis that supports regulatory submissions. Regulatory reviewers at the FDA and EMA received cleaner datasets with fewer queries, which OncoCure believed contributed to faster review cycles.

Site and Patient Experience

The digital transformation also improved the experience for clinical trial sites and patients. Sites benefited from simpler startup processes, faster query resolution, and better communication with the sponsor. The site satisfaction score improved from 6.8 to 8.9 out of 10, making OncoCure a more attractive partner for sites evaluating which sponsor trials to participate in. In the competitive world of clinical trial enrollment, site preference can significantly impact a company's ability to recruit patients and complete trials on schedule.

Key Success Factors and Lessons Learned

OncoCure's successful implementation of low-code clinical trial management offers valuable insights for pharmaceutical companies and clinical research organizations:

Start With the Most Painful Problem

OncoCure deliberately chose to start with study startup, which was the area of greatest operational pain and where improvements would be most visible. The success of the initial pilot built confidence and momentum that carried through to subsequent phases. Starting with a high-impact, visible use case also helped secure continued executive support and budget for the program.

Domain Experts as Application Builders

The involvement of clinical operations experts in the application development process was a critical success factor. OncoCure trained several clinical research associates and data managers to become citizen developers on the low-code platform, enabling them to configure workflows, business rules, and reports without waiting for IT resources. These domain experts brought deep understanding of clinical trial operations, regulatory requirements, and user needs that would have been difficult to capture through traditional requirements documentation.

Integration-First Architecture

Rather than building a standalone system, OncoCure designed the low-code platform as an integration and orchestration layer connecting existing systems. This approach preserved the company's investment in its commercial CTMS and EDC systems while adding capabilities that those systems could not provide. The integration-first approach also reduced implementation risk, since the existing systems continued to function as before while the new capabilities were gradually introduced.

Governance and Validation

In a regulated industry like pharmaceuticals, system validation and compliance are non-negotiable. OncoCure established a governance framework specifically for low-code development that addressed validation requirements, change control procedures, audit trail requirements, and user access management. The low-code platform's built-in audit logging, version control, and role-based access control capabilities satisfied regulatory requirements without requiring custom development. The company's quality assurance team was involved from the beginning of the project, ensuring that the governance framework met regulatory expectations.

How Does Low-Code Transform Clinical Trial Management Compared to Traditional Approaches?

OncoCure's experience highlights both the advantages and the limitations of low-code in the clinical research context:

Speed of Implementation

The low-code approach enabled OncoCure to implement its clinical trial management platform in 12 months, compared to the 18 to 24 months that a similar custom development project would have required. The visual development environment and pre-built components dramatically reduced the time needed to build forms, workflows, integrations, and reports. Regulatory-compliant audit trails and data security features were built into the platform rather than being developed from scratch.

Flexibility and Adaptability

The low-code platform's flexibility proved particularly valuable in the clinical trial context, where each trial has a unique protocol and requirements. Configuring a new trial in the platform took days rather than the weeks required to customize the commercial CTMS. When regulations changed or new safety reporting requirements emerged, the applications could be updated quickly across all active trials.

Can Low-Code Platforms Meet Regulatory Requirements for Clinical Systems?

This is a critical question for pharmaceutical companies evaluating low-code options. OncoCure validated that the low-code platform they selected met FDA requirements for systems used in clinical trials, including 21 CFR Part 11 compliance for electronic records and signatures, audit trail capabilities, user authentication, and data encryption. The platform underwent a formal validation process as part of OncoCure's quality management system, and the validation documentation was accepted by regulatory inspectors during an FDA audit.

What Training Is Needed for Clinical Staff to Build Applications?

OncoCure found that clinical operations staff with no prior programming experience could become productive citizen developers after two to three weeks of platform training and mentorship. The key was providing a structured training curriculum, ongoing support from the IT team, and a sandbox environment where they could experiment without affecting production systems. The most successful citizen developers were those who combined deep domain expertise with a systematic approach to problem-solving, even if they had never written a line of code.

Conclusion: The Future of Clinical Trial Technology

OncoCure Therapeutics' journey to modernize clinical trial management through low-code automation demonstrates that the pharmaceutical industry no longer needs to accept slow, rigid, paper-intensive trial processes as inevitable. By deploying a low-code platform as an orchestration and automation layer, the company reduced trial setup time by 57 percent, cut data errors by 84 percent, and accelerated regulatory submissions by 4.5 months per study. The financial impact was substantial, with millions in direct cost savings and the potential for hundreds of millions in accelerated revenue from faster drug launches.

For an industry where every day of delay can mean patients waiting longer for potentially life-saving treatments, the ability to accelerate clinical development timelines is not just a financial consideration — it has direct human impact. The $2.6 billion average cost of drug development is driven in large part by the inefficiency of clinical trial processes, and addressing those inefficiencies is one of the most promising paths to making drug development more affordable and faster.

Low-code platforms are not a replacement for specialized clinical trial systems like electronic data capture or safety databases. Rather, they offer a complementary capability — the ability to build custom workflows, integrations, and user experiences that adapt to the unique requirements of each trial and each organization. As the platform technology continues to mature and as more life sciences companies develop in-house low-code expertise, the clinical trial of the future will be managed by systems that are as dynamic and adaptable as the science they support.

Pharmaceutical companies considering clinical trial digitization should evaluate low-code platforms as a strategic component of their clinical technology architecture. The combination of speed, flexibility, regulatory compliance, and citizen development capability makes low-code a powerful tool for transforming clinical operations. OncoCure's experience provides a proven blueprint for organizations ready to modernize their approach to bringing new therapies to patients who need them.